The objectives of the Cancer Research Informatics Core (CRIC) are: 1. To maintain a cost-effective, user friendly and efficient cancer research informatics core resource for Cancer Center investigators. This Core oversees the computing resources needed for handling on-line clinical data entry, data from basic science experiments, and the data management and analytical requirements for epidemiological investigations, population survey and translational research. The main focus is on the design and development of research databases for the data acquisition needed for these research investigations. 2. To coordinate with the Biostatistics Core, the Translational Pathology Core, the Molecular Genomics Core and the Clinical Investigations Support Office (CISO) all research data management and applications for Cancer Center investigators. In this capacity, this Core provides user training in the use of the various databases and assists in software development, deployment, and maintenance. In addition, members of this Core consult on the acquisition of new computing equipment and software to insure its compatibility with existing hardware and software systems that are utilized for research activities. 3. To oversee and assist in the Center's caBIG deployment and adoption activities. 4. To coordinate with Cancer Center administration any data management needs for the research management and administrative needs of the Center. These activities are not funded by the CCSG.

Public Health Relevance

Access to and use of electronic information has become essential to most facets of cancer research. As our Cancer Center expands its translational research activities, there is a growing need for information systems that can capture and analyze data from all of the various research activities at the Center. Investigators in all of areas of the Center (population, clinical and basic sciences) are utilizing the expertise of the CRIC to accomplish their research goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-38
Application #
8567483
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
38
Fiscal Year
2013
Total Cost
$130,590
Indirect Cost
$47,488
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Eriguchi, Yoshihiro; Nakamura, Kiminori; Yokoi, Yuki et al. (2018) Essential role of IFN-? in T cell-associated intestinal inflammation. JCI Insight 3:
Battaglin, Francesca; Naseem, Madiha; Puccini, Alberto et al. (2018) Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell Int 18:99
Zhang, Junjie; Zhao, Jun; Xu, Simin et al. (2018) Species-Specific Deamidation of cGAS by Herpes Simplex Virus UL37 Protein Facilitates Viral Replication. Cell Host Microbe 24:234-248.e5
Suenaga, Mitsukuni; Schirripa, Marta; Cao, Shu et al. (2018) Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clin Colorectal Cancer 17:e395-e414
Thomas, Nancy E; Edmiston, Sharon N; Orlow, Irene et al. (2018) Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. J Invest Dermatol 138:2398-2404
Cobo, Eduardo R; Holani, Ravi; Moreau, France et al. (2018) Entamoeba histolytica Alters ileal Paneth Cell Functions in Intact and Muc2 Mucin Deficiency. Infect Immun :
Pinto, Navin; DuBois, Steven G; Marachelian, Araz et al. (2018) Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer 65:e27023
Hanna, Diana L; Loupakis, Fotios; Yang, Dongyun et al. (2018) Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clin Colorectal Cancer 17:e471-e488
Rhie, Suhn Kyong; Yao, Lijun; Luo, Zhifei et al. (2018) ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream of transcription start sites at the majority of CpG island promoters. Genome Res :
Darabedian, Narek; Gao, Jinxu; Chuh, Kelly N et al. (2018) The Metabolic Chemical Reporter 6-Azido-6-deoxy-glucose Further Reveals the Substrate Promiscuity of O-GlcNAc Transferase and Catalyzes the Discovery of Intracellular Protein Modification by O-Glucose. J Am Chem Soc 140:7092-7100

Showing the most recent 10 out of 842 publications